Your browser is out-of-date!

Update your browser to view this website correctly.

Disclaimer
To continue, please select your country of domicile and investor type. Depending on your domicile and the investor type that you select, you will have full or restricted access to the information due to legal reasons.

Retail clients: according to Art. 4 Abs. 2 FinSA

Professional/Institutional investors: according to Art. 4 paragraph 3-5 and Art. 5 paragraph 1 and 3-4 FinSA and Art. 10 paragraph 3 and 3ter CISA in conjunction with Art. 6a CISO

Important

Principles 

By using the website www.bellevue.ch, you confirm that you have read, understood and accepted the general information provided by the Bellevue Group AG as well as these legal provisions. These may be subject to change and the use of the site may be restricted or terminated at any time without prior notice.

No recommendation and/or offer for subscription (or for purchase) and/or redemption (or for sale)

The information, products, data, services, tools and documents contained or described on this site ("website content") are for information purposes only and constitute neither an advertisement or recommendation nor an offer or solicitation (to buy) or redemption (sell) investment instruments, to effect any transaction or to enter into any legal relations.

The financial products mentioned on this site are not suitable for all investors. The information contained on this site does not constitute a financial, legal, fiscal or any other recommendation. Investment or other decisions should not be made solely on the basis of this document. In particular, you should not enter into any investment before you have read the corresponding fund agreement or legal prospectus, the annual and semi-annual reports, the articles of association (as far as they are applicable), as well as all other documents, as required in accordance with local legislation or the regulations applied in the legal jurisdictions or countries in which the corresponding investment fund has been licensed or approved for public offer or sale to the public.rlich sind.

The financial products mentioned on this site are not suitable for all investors. The information contained on this site does not constitute a financial, legal, fiscal or any other recommendation. Investment or other decisions should not be made solely on the basis of this document. In particular, you should not enter into any investment before you have read the corresponding fund agreement or legal prospectus, the annual and semi-annual reports, the articles of association (as far as they are applicable), as well as all other documents, as required in accordance with local legislation or the regulations applied in the legal jurisdictions or countries in which the corresponding investment fund has been licensed or approved for public offer or sale to the public.

In order to determine whether the investment in shares of a certain investment fund meets your specific requirements and matches your envisaged risks, we recommend that you contact an independent financial adviser. Furthermore, we recommend that you consult an independent tax adviser in order to obtain information on the tax regulations relating to a specific investment in your legal jurisdiction and with regard to your personal circumstances. In particular tax treatment depends on individual circumstances and may be subject to change.

As the funds are recognised (ie. registered) but not authorised in the UK, the UK Financial Services Authority's financial services compensation scheme does not apply to investments in the fund but the Financial Services Authority regulated firm approving this document for the purposes of UK regulation has taken reasonable steps to satisfy itself that Bellevue will deal in an honest and reliable way and is so satisfied.

Performance

Past performance is not an indication or guarantee of the future performance of the investment. The value of investments may be subject to fluctuations and, under certain circumstances, investors may not get back the full amount invested. The performance data are calculated without taking account of commissions and costs that result from subscriptions and redemptions and commissions and costs have a negative impact on performance. Changes in foreign-exchange rates may also cause the value of investments to go up or down.

Target group of the sites 

The sites are intended exclusively for use by legal entities and natural persons having their registered office or residing in countries in which the investment funds or the related subfunds or share classes of the Bellevue Group have been properly licensed or approved for public offer or sale in accordance with the applicable local legislation. The funds are currently registered for public distribution offer in the following countries: Luxembourg, Switzerland, Germany, Austria, Spain and Portugal. In all other countries, the funds may, if any, via "Private Placement" according to the local applicable laws.

It is explicitly stated, that alternative fund products are not allowed for public distribution in any country and that they may only and exclusively be solicited to institutional and qualified private investors according to the applicable local laws of each country.

The information and services provided on the sites are not intended for offer to or use by legal entities or natural persons in legal jurisdictions or countries in which the offer or use thereof would violate local legislation or legal provisions, or in which business units forming part of Bellevue Group would be subject to registration requirements in such jurisdictions or countries. Legal entities or natural persons to which such prohibitions apply must not access or use these sites.

The Bellevue funds have NOT been licensed for public offer or sale to the public in the United States in accordance with the US Investment Company Act of 1940 or the US Securities Act of 1933, or in Canada, Japan, Taiwan, Malaysia, Hong Kong or Israel in accordance with the laws in force in those countries. Therefore, particular importance is attached to ensuring that these sites are not intended for legal entities or natural persons, who have their registered office or who reside in such countries, their territories or dependencies or who, on account of their citizenship or similar status, are subject to the law of one of these countries.

Fund documents Luxembourg Fund

Bellevue SICAV: The Bellevue Funds (Lux) SICAV is admitted for public offering and distribution in Switzerland . Representative agent in Switzerland   Waystone Fund Services (Switzerland) SA, Avenue Villamont 17, CH-1005 Lausanne and paying agent in Switzerland: DZ PRIVATBANK (Schweiz) AG Münsterhof 12, PO Box, CH-8022 Zürich. Austria: Paying and information agent: Zeidler Legal Process Outsourcing Limited., 19-22 Lower Baggot Street, Dublin 2, D02 X658, Ireland. Germany: information agent: Zeidler Legal Process Outsourcing Limited., 19-22 Lower Baggot Street, Dublin 2, D02 X658, Ireland. Spain: The Bellevue Funds (Lux) SICAV is registered with the CNMV under the number 938. Paying and information agent: atl Capital, Calle de Montalbán 9, ES-28014 Madrid.  Prospectus, Key Investor Information Document (“KID”), the articles of association as well as the annual and semi - annual reports of the Bellevue Funds under Luxembourg law are available free of charge from the above mentioned representative, paying, facilities and information agents as well as from Bellevue Asset Management AG, Seestrasse 16 , CH - 8700 Kusnacht. 

Bellevue Asset Management (Deutschland) GmbH: You can obtain the sales prospectus, the annual reports and the german key investor information documents free of charge from Bellevue Asset Management (Deutschland) GmbH, and also from banks and financial advisers. Paying agent in Switzerland is DZ PRIVATBANK (Schweiz) AG, Münsterhof 12, PO Box, CH-8022 Zurich. The swiss agent is IPConcept (Schweiz) AG, In Gassen 6, PO Box, CH-8022 Zurich. In Switzerland you can obtain sales prospectus, the annual reports and the german key investor information documents free of charge from the agent and also from the paying agent. 

Fund documents Bellevue Entrepreneur Switzerland

Prospectus, Key Investor Information Document („KID“), fund contract as well as the annual and semi - annual reports of the Bellevue Fund under Swiss law are available free of charge from: Switzerland : PMG Fonds Management AG, Dammstrasse 23, 6300 Zug or Bellevue Asset Management AG, Seestrasse 16, CH - 8700 Kusnacht. 

Fund documents Bellevue Funds and Bellevue Healthcare Strategy

Prospectus, Key Investor Information Document („KID“), fund contract as well as the annual and semi - annual reports of the Bellevue Medtech and Services fund established under Swiss law in the category "Other Funds for Traditional Investments" are available free of charge from : Switzerland : Swisscanto Fondsleitung AG, Bahnhofstrasse 9 , CH - 8001 Zürich or Bellevue Asset Management AG, Seestrasse 16 , CH - 8700 Kusnacht

Fund documents StarCapital Equity Value plus, StarCapital Multi Income, StarCapital Strategy 1 and StarCapital Dynamic Bonds.

Prospectus, the key investor information document ("KID"), the management regulations and the semi-annual and annual report are available free of charge in German from Bellevue Asset Management (Deutschland) GmbH, your advisor or intermediary, the paying agents, the relevant custodian bank or from the management company IPConcept (Luxembourg) S.A. (société anonyme), 4, rue Thomas Edison, L-1445 Luxembourg, Luxembourg, https://www.ipconcept.com. For information on opportunities and risks as well as tax information, please refer to the current detailed sales prospectus. Further information on investor rights can be found on the Management Company's website (https://www.ipconcept.com). The management company may decide to cancel the arrangements it has made for the distribution of the units of its collective investment undertakings in accordance with Article 93a of Directive 2009/65/EC and Article 32a of Directive 2011/61/EU.

Fund documents Bellevue Option Premium fund

Prospectus, the key investor information document ("KID"), the management regulations and the semi-annual and annual reports are available free of charge in German from Bellevue Asset Management (Deutschland) GmbH, your advisor or intermediary, the paying agents, the responsible depositary (UBS Europe SE, Bockenheimer Landstrasse 2-4, D-60306 Frankfurt am Main) or from the management company Universal-Investment-Gesellschaft mbH, Theodor-Heuss-Allee 70, D-60486 Frankfurt am Main, https://www.universal-investment.com. For information on opportunities and risks as well as tax information, please refer to the current detailed sales prospectus. Further information on investor rights can be found on the Management Company's website (https://www.universal-investment.com). The management company may decide to cancel the arrangements it has made for the distribution of the units of its collective investment undertakings in accordance with Article 93a of Directive 2009/65/EC and Article 32a of Directive 2011/61/EU.

 Fund documents StarCapital Premium Bonds plus  

Prospectus, the key investor information document ("KID"), the management regulations and the semi-annual and annual reports. These can be obtained free of charge in German from Bellevue Asset Management (Deutschland) GmbH, your advisor or intermediary, the paying agents, the responsible depositary (UBS Europe SE, Bockenheimer Landstrasse 2-4, D-60306 Frankfurt am Main) or from the management company Donner & Reuschel AG, Ballindamm 27, 20095 Hamburg, https://www.donner-reuschel.de. For information on opportunities and risks as well as tax information, please refer to the current detailed sales prospectus. Further information on investor rights can be found on the Management Company's website (https://www.universal-investment.com). The management company may decide to cancel the arrangements it has made for the distribution of the units of its collective investment undertakings in accordance with Article 93a of Directive 2009/65/EC and Article 32a of Directive 2011/61/EU.

Data protection

By accessing this website you state that you agree with the data protection statement. If you do not agree with this statement you should refrain from accessing any further pages of this website. This statement may be updated at any time. We therefore recommend that you check this statement regularly.

Confirmation

By clicking on "Accept", you confirm that you agree to the legal provisions. 

Algorithms and big data platforms are increasingly important factors in the research and development of new drugs. A study published in Nature Computational Science in which BB Biotech team members collaborated with distinguished experts from Duke University examined the medical, financial, and commercial value that can be generated using the latest technological solutions.

The impact of algorithms and big data on drug discovery and development processes: An empirical study

Algorithms and big data platforms are increasingly important factors in the research and development of new drugs. A study published in Nature Computational Science in which BB Biotech team members collaborated with distinguished experts from Duke University examined the medical, financial, and commercial value that can be generated using the latest technological solutions.
12.06.2024

Computational science refers to the design and use of artificial intelligence tools and computer simulations and it is becoming established across an ever-wider spectrum of the drug discovery and development process. Biotech companies are leading the charge. Drug makers are expecting the widespread development of AI algorithms and big data platforms to benefit their own drug research and development activities in many ways. Connecting and evaluating data using AI will save them both time and money during the preclinical and clinical phases of drug development. Drug makers are also seeking to steadily reduce the risk of clinical failure thanks to the increasing accuracy and precision of their data analysis capabilities. Last but not least, AI-optimized drug discovery processes are being used to identify clinical targets with molecular structures that offer a clearly superior mechanism of action in a wide range of therapeutic areas. 

Many drug developers are developing their own algorithms and big data platforms to leverage their in-house clinical and scientific data and setting up new hardware systems, as they seek to enhance their R&D pipelines with AI and big-data computing capabilities. In pursuit of these objectives, they are, on the one hand, deploying machine learning tools in data analysis and, on the other hand, conducting computer simulations in the design, development, and clinical testing of new drugs. In practical terms, the technologies are being used throughout the various phases of preclinical and clinical R&D – from target selection and the identification and optimization of lead compounds to the selection of patients for a clinical trial.

A study analyzing AI and drug discovery
BB Biotech recognized early on that automated algorithms can be used within the scope of its own investment process to analyze the growing mountain of data generated by the biopharmaceutical industry more efficiently. In an internal project called BioCarta managed by three data scientists on the company’s payroll, it created a proprietary data pool along with the necessary analytics software, big data apps, and hardware.

BB Biotech’s Investment Management team and external experts  conducted a study to obtain an overview of how and to what extent computational science can improve future drug discovery and development processes. A total of 90 companies that claim that computational science is a crucial component of their operating business and that also met certain criteria specified by BB Biotech were covered in this study.

Their business models, strategies and funding profiles were examined in the study. There were some major differences between the business models. More than half of the 90 companies are services providers. The remaining 41% of the companies are partnering with pharmaceutical companies in the development of up to 49% of their pipeline projects. In effect, this means that only 21% of the companies studied are applying the latest computer science technology in the development of their pipeline projects and financing these activities on their own.

Focus on algorithms and early-stage research
93% of the companies surveyed say that the new algorithms they are using give them an advantage over the competition in the drug discovery and development process. However, only 6.5% of the companies say that the hardware they use gives them a competitive advantage. This discrepancy can largely be traced to cost factors. New algorithms can be developed at relatively low cost, whereas it takes considerably more capital to buy the necessary hardware. This hardware is mainly used for drug design and target identification purposes, primarily to predict molecular drug-target interactions. That information is then used to draw conclusions about molecular interaction and binding affinity. Relay Therapeutics, a biotech company in which BB Biotech is invested, and Modulus Discovery are using this approach in their drug development pipelines.

37% of the companies surveyed say that the integration of AI-based data sets into their R&D pipeline has advanced their biological and clinical understanding of a targeted disease or condition. Most of the companies that have integrated AI-based data into their pipeline are still in the early stages of clinical development, except for a few exceptions (such as Recursion).

Only 28% of the drug companies analyzed in the study have proprietary products at an advanced stage of clinical development with proven efficacy. Computational science technology is being used most often to determine profiles for clinical trials and for clinical trial participants. AI still plays a minor role in determining active ingredients and managing safety aspects: A mere 2.2% and 4.1%, respectively, of the companies surveyed use computer-based data for these purposes. The physiological complexity of the molecules is considered one of the greatest challenges when conducting in silico studies (drug R&D conducted exclusively on a computer or via computer simulation), along with the high cost of in vivo testing, i.e. drug R&D carried out with or in living organisms. In silico-based toxicological studies in novel therapeutic applications are still not widely accepted by regulators. That could change in the US, where the FDA is endeavoring to ease the regulations for in vivo studies, which could lead to the greater standardization of in silico protocols. This would lead to greater recognition of these protocols in regulatory processes.

More partnering deals and IPOs
An analysis of the funding profiles of companies with a self-developed or partnered R&D pipeline showed that private equity vehicles and equity funds have provided the most capital to early-phase companies using their own algorithms. Companies that are using their own AI tools, either for preclinical drug discovery purposes or in early phase clinical trials, have raised an average of USD 237 mn in outside funding. The average amount of funding provided to companies developing algorithms for analyzing patient data is slightly higher at USD 300 mn. The picture is quite different at companies that are focused on capital-intensive hardware: They have raised an average of USD 622 mn.

Judging by the increasing number of IPOs over the past three years and the generally growing investment inflows, the segment of biotech companies actively applying computational science is maturing and developing. Partnership deals involving the pharmaceutical industry have clearly been focused on services, which is reflected in the large number of companies in the study whose business models center on services and not on drug discovery and development. Looking ahead, it will be exciting to see if and how the number of collaboration agreements in which computer-based technology is integrated into late-stage clinical development projects increases. A key argument here will be the potential cost savings in pivotal clinical trials: The bulk of a drug's total R&D cost is incurred during this phase of drug development.

Commercial added value
Commercial added value is a key question that was raised already during the planning process for the study: How will computational science generate value with respect to new drug approvals, both in terms of their number and the therapeutic benefit of the approved drugs? Clear conclusions cannot yet be drawn here. 71% of all pipeline projects are still in a preclinical phase of development. The modalities currently in Phase I or II clinical trials will be crucial in determining whether AI and big data will help companies to bring more effective and cheaper drugs to the market going forward. Currently, most of the companies covered by the study are focused on algorithms and target validation, primarily in the two areas of oncology and neurological disorders. In view of the molecular structures of therapeutic antibodies and peptides, and the growing number of regulatory approvals, it is conceivable that AI could help to lower the high manufacturing costs associated with these drugs. At present, small molecule drugs still account for 61% of all ongoing R&D projects in which AI-based technology is being applied.

Therefore, it is too early to draw any specific conclusions comparing the success of computational science in drug R&D projects with the success rates of drug R&D projects that use other technologies. The growing number of collaboration agreements is a clear sign that computational drug research and development has attained a new level of maturity. The developments and outcomes of the coming years will show to what extent computational science can accelerate the development and commercialization of innovative drugs. BB Biotech’s Investment Management Team will continue to closely monitor sector developments, engaging early on with companies pursuing novel approaches and platform technologies, and ultimately make its investment decisions based on specific arguments rather than, say, on the vague potential of a certain platform.

Three specialists in BB Biotech’s investment portfolio

BB Biotech is currently invested in three biotech companies that have made computational science an important factor in their research and development activities.

 


  • Relay Therapeutics’ Dynamo platform integrates cutting-edge experimental and computational approaches that give it a differentiated understanding of protein structure and motion. The company is focused on precision medicine with the aim of eliminating disease-causing proteins that were previously considered undruggable targets. The company has three cancer treatments in early clinical development. 

  • Black Diamond is also a precision oncology medicine company. The company is applying machine learning to develop therapies for inherited cancers that are effective regardless of the given tumor type. The company's proprietary MAP platform is designed to allow it to analyze population-level genetic sequencing data. In an initial step, oncogenic mutations that promote cancer across tumor types are identified. These mutations are then grouped into families with similar protein structures. Based on these findings, the company is developing single small molecule therapies in a tumor-agnostic manner that target a specific family of mutations.

  • Moderna, a core portfolio position, is deploying digital tools to significantly accelerate the entire process from the screening and design conception of mRNA-based therapeutics to their clinical development, as it did with its COVID-19 vaccine sold under the brand name Spikevax. mRNA Design Studio played a key role here. mRNA Design Studio is a web-based platform that utilizes cloud-based computational capacity and is connected with digital drug design tools and a highly automated production facility. A sequence designer module allows researchers to quickly design multiple mRNA sequences for a specific protein target that are then automatically converted to an initial optimized mRNA sequence.